Skip to main content
Premium Trial:

Request an Annual Quote

WellGen Names New CEO; Craig Mello Wins New Paul Janssen Award; Decode Adds a Director; Tm Names New SAB Chair; and Others

NEW YORK (GenomeWeb News) – Chip-Man Technologies has appointed Jane Spencer-Fry as vice president of European sales.
 
Spencer-Fry comes to Chip-Man from BioVeris Europe, where she was most recently sales director. She has also held a “variety” of commercial and scientific roles with Packard Biosciences (now PerkinElmer) and Amersham International.

 
Nutrigenomics company WellGen has appointed Kathleen Mullinix as its new CEO effective immediately to succeed David Evans, who passed away on June 1.
 
Mullinix previously was an advisor to investors on biotechnology and pharmaceutical business opportunities through her company Kathleen P. Mullinix & Associates, which she founded in 2002.  Before that, Mullinix served as the founder, chairman, CEO and president of Synaptic Pharmaceutical
 
She has a BA in chemistry from Trinity College and a PhD in chemical biology from Columbia University.

 
Craig Mello, professor of molecular medicine at the University of Massachusetts Medical School, has been named the inaugural recipient of The Dr. Paul Janssen Award for Biomedical Research.
 
Mello, who is also an investigator at the Howard Hughes Medical Institute, was selected for “his role in the discovery of RNA interference and the elucidation of its biological functions,” according to a statement released by Johnson & Johnson, which established the award.
 
The award includes a $100,000 prize. It will be given every two years.

 
Decode Genetics appointed Peter Goodfellow to its board of directors, effective immediately.
 
Goodfellow was until recently senior vice president for discovery research at GlaxoSmithKline. He received his PhD from Oxford University.

 
Tm Bioscience has appointed Donald Low as chairman of its scientific advisory board, effective immediately. He replaces Brad Popovich, who will no longer serve on the company's SAB.
   
Low is a professor of medicine and microbiology at the University of Toronto; head of the Division of Microbiology in the Department of Laboratory Medicine and Pathobiology at the University of Toronto; medical director of Public Health Laboratories; and chief of the Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology.


 
ExonHit Therapeutics has hired John Jaskowiak as executive vice president of business and marketing. Jaskowiak will work out of the company’s US subsidiary in Gaithersburg, Md.
 
Jaskowiak comes to ExonHit from Affymetrix, where he was senior director of marketing. His goal at ExonHit will be to “develop a partnering business model for ExonHit's genomics efforts to expand ExonHit's business in diagnostics and personalized medicines."

 
On Sept. 1, CuraGen entered into agreements with the following executives that enables them to remain “employed on a full-time basis, continuing at will until either party gives notice of termination:” Frank Armstrong, president and CEO; Paul Finigan, senior vice president and general counsel; Timothy Shannon, executive vice president and chief medical officer; Elizabeth Whayland, senior vice president of finance and corporate secretary; David Wurzer, executive vice president and CFO and treasurer; and subsidiary 454 Life Sciences President and CEO Christopher McLeod.

 
Gene Logic has extended until Dec. 31 the employment of Larry Tiffany as senior vice president and interim general manager of its Genomics Division. The company originally signed him up for these duties on June 30 and said he would remain employed until Aug. 31.

 
iAdvantage Software has hired Richard Hellmer as director of business development and Bob Winters as senior account executive.
 
Hellmer comes to iAdvantage from Nervana, where he was regional director. He received his BS in biochemistry from Virginia Tech.
 
Winters comes to iAdvantage from BASi, where he was senior director of business development.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.